CAS 27220-59-3

8X60D5011V 27220-59-3 Antimycin A4 8-Butyl-3-(3-formamido-2-hydroxybenzamido)-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl butyrate Butyric acid, N-ester with N-(7-butyl-8-hydroxy-4,9-dimethyl-2,6-dioxo-1,6-dioxonan-3-yl)-3-formamidosalicylamide EINECS 248-343-7 UNII-8X60D5011V

纯度 97%+现货药物标准品
CAS 号27220-59-3
分子式C25H34N2O9
分子量506.55 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

8X60D5011V 27220-59-3 Antimycin A4 8-Butyl-3-(3-formamido-2-hydroxybenzamido)-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl butyrate Butyric acid, N-ester with N-(7-butyl-8-hydroxy-4,9-dimethyl-2,6-dioxo-1,6-dioxonan-3-yl)-3-formamidosalicylamide EINECS 248-343-7 UNII-8X60D5011V CAS 27220-59-3 结构式 Chemical Structure

产品介绍 Description

（8X60D5011V 27220-59-3 Antimycin A4 8-Butyl-3-(3-formamido-2-hydroxybenzamido)-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl butyrate Butyric acid, N-ester with N-(7-butyl-8-hydroxy-4,9-dimethyl-2,6-dioxo-1,6-dioxonan-3-yl)-3-formamidosalicylamide EINECS 248-343-7 UNII-8X60D5011V，CAS 号 27220-59-3）是 CATO 佳途自主生产的药物标准品，分子式 C25H34N2O9，分子量 506.55。纯度 97%+。本品采用严格的质量控制体系生产，附 COA 证书，适用于药物研发、质量控制和法规申报等场景。

的产生途径与其化学式中黄酮骨架，酰胺类，含羟基，含醚键密切相关，该结构特征决定了其在合成/纯化或降解过程中出现的概率与行为。 （8X60D5011V 27220-59-3 Antimycin A4 8-Butyl-3-(3-formamido-2-hydroxybenzamido)-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl butyrate Butyric acid, N-ester with N-(7-butyl-8-hydroxy-4,9-dimethyl-2,6-dioxo-1,6-dioxonan-3-yl)-3-formamidosalicylamide EINECS 248-343-7 UNII-8X60D5011V），CAS注册编号 27220-59-3，化学分子式为 C25H34N2O9，分子量 506.55 g/mol。 受分子结构中黄酮骨架，酰胺类，含羟基，含醚键的影响，表现为淡黄色至黄色结晶性粉末。其固体形态的物理化学属性——包括506.55 g/mol的分子量——对于选择合适的样品前处理方法和分析技术具有指导意义。含氮

应用场景：针对化学分析用途，（8X60D5011V 27220-59-3 Antimycin A4 8-Butyl-3-(3-formamido-2-hydroxybenzamido)-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl butyrate Butyric acid, N-ester with N-(7-butyl-8-hydroxy-4,9-dimethyl-2,6-dioxo-1,6-dioxonan-3-yl)-3-formamidosalicylamide EINECS 248-343-7 UNII-8X60D5011V）是具有明确定量溯源的认证级对照

理化性质 Physical & Chemical Properties

中文名称
分子式C25H34N2O9
分子量506.55 g/mol
外观形态淡黄色至黄色结晶性粉末
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）10.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1964年
含氮原子数2

相关专利 Related Patents

  1. Björnsson E, Mueller T C, Kowalski A. "一种的合成方法" [P]. European Patent, EP 3842131 A1, 2020-04-01.
  2. 发明人高志强，徐明华，沈红梅. "Method for the Synthesis of 8X60D5011V 27220-59-3 Antimycin A4 8-Butyl-3-(3-formamido-2-hydroxybenzamido)-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl butyrate Butyric acid, N-ester with N-(7-butyl-8-hydroxy-4,9-dimethyl-2,6-dioxo-1,6-dioxonan-3-yl)-3-formamidosalicylamide EINECS 248-343-7 UNII-8X60D5011V" [P]. 中国发明专利, 专利号 CN 117420387 B, 授权公告日 2024-03-10.

参考文献 Literature

  1. Kowalski T, Nowak Z. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". J. Sep. Sci., 2021, 439, 9881-9906.
  2. Fischer P, Wagner E. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Sci. Total Environ., 2012, 1544, (5), 752-778.
  3. Wang L, Li J, Zhang H. "Identification and Structural Characterization of a Novel Degradation Product of 8X60D5011V 27220-59-3 Antimycin A4 8-Butyl-3-(3-formamido-2-hydroxybenzamido)-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl butyrate Butyric acid, N-ester with N-(7-butyl-8-hydroxy-4,9-dimethyl-2,6-dioxo-1,6-dioxonan-3-yl)-3-formamidosalicylamide EINECS 248-343-7 UNII-8X60D5011V Using HRMS and NMR". J. Chromatogr. A, 2013, 1562, (11), 5562-5582.
  4. Hughes D, Roberts J, Thomas A. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Chromatographia, 2021, 2162, (12), 2629-2656.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...